OnKure Therapeutics Financial Results
OnKure Therapeutics reported third quarter 2026 financial results and provided updates on its PI3Kα pan-mutant-selective inhibitor pipeline. The company remains on track to submit IND applications for OKI-355 (vascular anomalies) and OKI-345 (breast cancer) in the first half of 2027, while also launching the PANORAMA disease registry.
“We continue to advance the development of next-generation PI3Kα pan-mutant-selective inhibitors through our pipeline, including OKI-355 in vascular anomalies and OKI-345 in breast cancer. Both of our lead programs remain on track for IND submissions in the first half of 2027.”
Nicholas Saccomano, Ph.D., President and Chief Executive Officer
“People living with vascular anomalies remain underserved, and we believe OnKure has an opportunity to help shape the future of treatment for this community. Mutations in the PIK3CA gene drive a range of vascular malformations, providing a compelling rationale for our development of OKI-355, which is designed to provide broad coverage across these mutations.”
Samuel Agresta, M.D., Chief Medical Officer